Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life

Biology of the Neonate

Volumn 86, Issue 3, 2004, Pages 207-211

  Allegaert, K ^a   Cossey, V ^a   Langhendries, J P ^b   Naulaers, G ^a   Vanhole, C ^a   Devlieger, H ^a   Van Overmeire, B ^c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Division of Neonatology   (Belgium)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Amikacin pharmacokinetics; Drug interactions; Ibuprofen lysine co administration; Preterm infants

Indexed keywords

AMIKACIN; IBUPROFEN LYSINE; PLACEBO;

ARTICLE; CALCULATION; CLINICAL TRIAL; COHORT ANALYSIS; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; FEMALE; GESTATIONAL AGE; HUMAN; LIFE; MAJOR CLINICAL STUDY; MALE; NEWBORN; PREMATURITY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY;

AMIKACIN; BACTERIAL INFECTIONS; DOUBLE-BLIND METHOD; GESTATIONAL AGE; HALF-LIFE; HUMANS; IBUPROFEN; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INFUSIONS, INTRAVENOUS; LYSINE; METABOLIC CLEARANCE RATE; PLACEBOS; RETROSPECTIVE STUDIES;

EID: 5644259541     PISSN: 00063126     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079618     Document Type: Article

References (20)

1. Mattie H: The importance of pharmacokinetics and pharmacodynamics for effective treatment of infections. Clin Investig 1993;71:480-482.
2. Moore RD, Lietman PS, Smith CR: Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155:93-99.
3. Langhendries JP, Battisti O, Bertrand JM, François A, Kalenga M, Darimont J, Scalais E, Wallemacq P: Adaptation in neonatology of the once-daily concept of aminoglycoside administration: Evaluation of a dosing chart for amikacin in an intensive care unit. Biol Neonate 1998;74:351-362.
4. Langhendries JP, Battisti O, Bertrand JM, François A, Darimont J, Ibrahim S, Tulkens PM, Bernard A, Buchet JP, Scalais E: Once-aday administration of amikacin in neonates: Assessment of nephrotoxicity and ototoxicity. Dev Pharmacol Ther 1993;20:220-230.
5. Treluyer JM, Merle Y, Tonnelier S, Rey E, Pons G: Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants and children. Antimicrob Agents Chemother 2002;46:1381-1387.
6. Bleyzac N, Varnier V, Labaune JM, Corvaisier S, Maire P, Jelliffe RW, Putet G, Aulagner G: Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation. Eur J Clin Pharmacol 2001;57:499-504.
7. Van den Anker JN: Pharmacokinetics and renal function in preterm infants. Acta Paediatr 1996;85:1393-1399.
8. Van Overmeire B, Smets K, Lecoutere D, Van de Broek H, Weyler J, Degroote K, Langhendries JP: A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 2000;343:674-681.
9. Lago P, Bettiol T, Salvadori S, Pitassi I, Vianello A, Chiandetti L, Saia OS: Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: A randomised controlled trial. Eur J Pediatr 2002;161:202-207.
10. Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, Solimano A, Vincer M, Wright LL; Trial of Indomethacin Prophylaxis in Preterms Investigators: Long-term effects of indomethacin prophylaxis in extremely-lowbirth-weight infants. N Engl J Med 2001;344:1966-1972.
11. Ment LR, Oh W, Ehrenkranz RA, Philip AG, Vohr B, Allan W, Duncan CC, Scott DT, Taylor KJ, Katz KH, Schneider KC, Makuch RW: Low-dose indomethacin and prevention of intraventricular hemorrhage: A multicenter randomized trial. Pediatrics 1994;93:543-550.
12. Van Overmeire B, Casaer A, Allegaert K, Debauche C, Decaluwé W, Debauche C, Jespers A, Weyler J, Langhendries JP: The prophylactic administration of ibuprofen in premature infants (abstract). Pediatr Res 2002;51:379.
13. Barr J, Brenner-Zada G, Heiman E, Pareth G, Bulkowstein M, Greenberg R, Berkovitch M: Unlicensed and off-label medication use in a neonatal intensive care unit: A prospective study. Am J Perinatol 2002;19:67-72.
14. Williams PD, Bennett DB, Gleason CR, Hottendorf GH: Correlation between renal membrane binding and nephrotoxicity of aminoglycosides. Antimicrob Agents Chemother 1987;31:570-574.
15. Koren G, Klein J, MacLeod SM: The dissociation between aminoglycoside serum concentrations and nephrotoxicity. Life Sci 1988;43:1817-1823.
16. Kenyon CF, Knoppert DC, Lee SK, Vandenberghe HM, Chance GW: Amikacin pharmacokinetics and suggested dosage modifications for the preterm infant. Antimicrob Agents Chemother 1990;34:265-268.
17. Petersen PO, Wells TG, Kearns GL: Amikacin dosing in neonates: Evaluation of a dosing chart based on population pharmacokinetic data. Dev Pharmacol Ther 1991;16:203-211.
18. Hartmann SE, Langhendries JP, Debauche C, Bernard A, Van Overmeire B: The influence of ibuprofen on renal tubular function in extremely low birth weight infants: A multicenter placebo-controlled evaluation (abstract). Pediatr Res 2002;51:338.
19. Guignard JP: The adverse renal effects of prostaglandin-synthesis inhibitors in the newborn rabbit. Semin Perinatol 2002;26:398-405.
20. Chamaa NS, Mosig D, Drukker A, Guignard JP: The renal hemodynamic effects of ibuprofen in the newborn rabbit. Pediatr Res 2000;48:600-605.